Top Breaking News | More News | Featured Stories | News By Subject | Event News | Investor News | News Archive | Search News
Get Our FREE
Industry eNewsletter
email:    

Investor News

Clinical Development News
Pre-Clinical
IND
Phase I - Safety
Phase II - Safety and Efficacy
Phase III - Controlled Safety and Efficacy
BLA/NDA/ANDA
PDUFA
Approvable Letters
Approval and Marketing Clearance
Post-Approval
Discontinued
Recalls and Warnings

Deals & Dollars News
Alliances
Earnings Reports
Financial
Investor
Mergers and Acquisitions
Start-Ups

IPO News
IPO


Clinical - Phase III
Cardiorentis Completes Enrollment In Pivotal Phase III Clinical Trial Of Ularitide For Acute Heart Failure 5/22/2015 6:08:41 AM
Analysts Question Intercept Pharma (ICPT) NASH Trial Phase III Length and Size 5/19/2015 10:39:54 AM
Johnson & Johnson (JNJ) Announced 10 New Approval Applications with $1 Billion Revenue Potential Each 5/20/2015 6:44:18 AM
IntelliPharmaCeutics Intends To Accelerate Its Rexista(TM) Oxycodone XR Development Program On The Basis Of Positive Feedback From The FDA 5/21/2015 10:26:01 AM
Novartis AG (NVS) Reports Two Positive U.S. Phase III Programs in COPD 5/20/2015 12:26:31 PM
Sunovion Pharmaceuticals Inc. Announces Positive Results for Latuda(Lurasidone HCL) In First Placebo-Controlled Trial Of Patients With Major Depressive Disorder With Mixed (Subsyndromal Hypomanic) Features 5/20/2015 12:18:40 PM
Alnylam (ALNY) Receives Orphan Drug Designation From The United States FDAFor Revusiran, An Investigational Rnai Therapeutic For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) 5/20/2015 12:06:36 PM
Boehringer Ingelheim Release: New Data Analyses On Investigational Tiotropium/Olodaterol Respimat Showed Greater Lung Function Improvement Compared To Tiotropium And Olodaterol Alone 5/20/2015 11:05:32 AM
Boehringer Ingelheim Release: New Data Show Benefit Of Tiotropium/Olodaterol Respimat From The Start Of COPD Maintenance Therapy1,2,3 5/20/2015 11:36:24 AM
Bristol-Myers Squibb (BMY) Receives Amended FDA Breakthrough Therapy Designation For Investigational Daclatasvir-Based Hepatitis C Regimen 5/20/2015 11:20:57 AM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Study Demonstrates Significant Burden Of Obesity On Patients' Recovery From Acute Bacterial Skin Infections 5/20/2015 8:10:56 AM
Eleven Biotherapeutics (EBIO) Stock Nosedives 80% Premarket as Eye Drug Flunks Phase III Test 5/18/2015 6:14:51 AM
Janssen Enters Into A Worldwide Collaboration With Achillion (ACHN) To Combat Hepatitis C Virus 5/19/2015 12:50:11 PM
Analysis Of Phase II Data For Celgene (CELG)’s Investigational Oral GED-0301 In Patients With Active Crohn’s Disease Presented At Digestive Disease Week 5/19/2015 12:39:38 PM
Janssen Pharmaceuticals, Inc. Release: U.S. FDA Approves INVEGA TRINZA, First and Only Four-Times-A-Year Treatment For Schizophrenia 5/19/2015 6:31:10 AM
1234567
//-->